Advanced Search

 

Study ID Status Title Patient Level Data
3065A1-107 Completed A 30-day safety and tolerability study of various titration regimens of retigabine in healthy male subjects
3065A1-108 Completed A study of the metabolic pathways and mass balance of orally administered [14C]-labeled Retigabine in healthy male subjects
3065A1-109 Completed An open-label, drug interaction study of retigabine and lamotrigine in healthy male subjects
3065A1-110 Completed A Comparative Bioavailability study of three oral dose formulations of retigabine in healthy adult subjects
3065A1-112 Completed A study of the potential effect of retigabine on the pharmacokinetics of an oral contraceptive containing norgestral and ethinyl estradiol in healthy female subjects
3065A1-113 Completed An open label drug interaction study of retigabine and Phenobarbital in healthy male subjects
3065A1-115 Completed Pharmacokinetics of Retigabine and its N-Acetylated Metabolite (NAMR) and the Impact on Serum Bilirubin in Subjects with Different Genotypes for UDP-glucuronyl transferase 1A1 (UGT1A1) and N-acetyl transferase (NAT2) Study Listed on ClinicalStudyDataRequest.com
3065A1-117 Completed Tolerability of intravenous dose titration of retigabine administered as short time infusion in healthy male volunteers Study Listed on ClinicalStudyDataRequest.com
3065A1-120 Completed Relative bioavailability of retigabine (D-23129) from various modified release formulations (TESTS) versus immediate release capsules (REFERENCE) in healthy male volunteers – second study
3065A1-121 Completed A study of the effects of blood collection processing on measured retigabine concentrations in healthy male volunteers
3065A1-123 Completed Absolute and Relative Bioavailability of Retigabine IR capsules in Healthy Male Subjects Study Listed on ClinicalStudyDataRequest.com
3065A1-200/201 Completed Efficacy, Tolerability, Safety and Pharmacokinetics of orally administered D-23129 in patients with partial onset seizures
3065A1-202 Completed A Multicenter, Open-Label, Safety, Tolerability, and Preliminary Efficacy Study of GKE-841 (Retigabine, D-23129) Administered as Add-On Therapy to Patients with Epilepsy Currently Receiving Monotherapy with an Established Anticonvulsive Agent
3065A1-205 Completed A Randomized, Double-blind, Placebo-controlled, Parallel group, Multicenter, Dose-ranging, Efficacy and Safety Study of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients With Partial Epilepsy Study Listed on ClinicalStudyDataRequest.com
3065A1-208 Completed A multicenter, open-label, long-term, safety tolerability, and efficacy study of GKE-841 (retigabine D-23129) in adult patients with epilepsy (extension of study 202) Study Listed on ClinicalStudyDataRequest.com
3065A1-209 Completed An Open-Label, Sequential-Group Feasibility Study to Assess the Tolerability of Rapid Dose Escalation of Retigabine in Epileptic Patients Under Ongoing Presurgical Assessment
3065A1-212 Completed A multicenter, open-label, long-term, safety tolerability, and efficacy study of retigabine in adult patients with epilepsy (extension of study 205) Study Listed on ClinicalStudyDataRequest.com
3065A1-214 Completed A Randomized, Double-Blind, Parallel-Group, Exploratory Safety and Tolerability Study of 3 Titration Rates of Retigabine (D-23129; GKE-841) Administered as Add-on Therapy in Patients with Refractory Partial Epilepsy Study Listed on ClinicalStudyDataRequest.com
3065A1-216 Completed A Multicenter, Open-Label, Long-Term Extension, Safety and Tolerability Study of Retigabine (GKE-841) in Adult Patients with Epilepsy Study Listed on ClinicalStudyDataRequest.com
347414/008 Completed Study to assess immunogenicity and safety of GSK Biologicals’ investigational vaccination regimen administered concomitantly in separate injections with GSK Biologicals’ DTPa-IPV/Hib vaccine as a primary vaccination course to healthy infants at 2-4-6 months of age and as a booster dose at 12 to 18 months of age Study Listed on ClinicalStudyDataRequest.com
347414/010 Terminated Assess, in young children, the efficacy in preventing acute otitis media (AOM) of GSK Biologicals undecavalent pneumococcal-protein D conjugate vaccine, when administered as a three dose primary vaccination course during the first year of life with a booster dose in the second year of life. Study Listed on ClinicalStudyDataRequest.com
347414/016 Completed A phase II, single-blind, randomised, controlled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of two experimental formulations versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix™ or HibTiter™) administered as primary vaccination to infants in their thirth, fourth and fifth months of life, with concomitant administration of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine Study Listed on ClinicalStudyDataRequest.com
347414/017 Completed A multinational, randomised, controlled, single-blind, phase-II study to evaluate the safety and immunogenicity of two investigational vaccination regimens versus a licensed Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix) given concomitantly with DTPw-HBV vaccine in a separate injection of DTPw-HBV to infants at 2, 4, and 6 months of age Study Listed on ClinicalStudyDataRequest.com
347414/020 Completed A Phase III, randomized, single blind study to assess the immune response induced by Prevenar™(Wyeth Lederle) when administered to healthy infants with DTPa-HBV-IPV/Hib, compared to an investigational vaccination regimen as a 3-dose primary vaccination course at a monthly interval starting at 8–16 Weeks of age Study Listed on ClinicalStudyDataRequest.com
347414/023 Completed A phase II, single-blind, randomized, controlled study to evaluate the immunogenicity and safety of four different formulations of an investigational vaccination regimen when given intramuscularly as primary vaccination in infants at 3, 4 ½ and 6 months of age. Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.